J.P. Morgan Notebook, Jan. 15: Kite, Vivus, Amarin
This article was originally published in The Pink Sheet Daily
Executive Summary
“The Pink Sheet” DAILY’s round-up of news and notes from the last day of the J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks
Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.
J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.